Predicine Announces Collaboration With Janssen To Develop PredicineCARE As A Companion Diagnostic Assay In Localized Bladder Cancer
Portfolio Pulse from Benzinga Newsdesk
Predicine, Inc. has announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PredicineCARE™, a urine cfDNA NGS assay, as a companion diagnostic tool for localized bladder cancer. The assay, which received FDA Breakthrough Device Designation, aims to identify patients who may benefit from targeted therapy by detecting genomic alterations in key cancer-associated genes.
January 08, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson, through its Janssen subsidiary, is collaborating with Predicine to develop a diagnostic assay for bladder cancer, which could enhance patient treatment options and potentially boost Janssen's product portfolio.
The collaboration with Predicine positions JNJ to potentially expand its oncology diagnostic portfolio, which could lead to increased use of its targeted therapies. The FDA's Breakthrough Device Designation for PredicineCARE™ suggests a high potential for regulatory success and market adoption, which could positively impact JNJ's stock in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80